EGFR-IN-60 is a novel inhibitor of EGFRWT, EGFRT790M, EGFRL858R and JAK3 with anticancer activity. It has IC50s of 83, 26, 53, and 69 nM, respectively.
Physicochemical Properties
| CAS # | 2699877-43-3 |
| PubChem CID | 164517080 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 37 |
| Complexity | 1070 |
| Defined Atom Stereocenter Count | 0 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | EGFR-IN-60 (Compound 7d) exhibited strong anti-tumor activity against HepG2, HCT-116, and MCF-7 breast cancer cells during a 48-hour period (3.25-88.46 μM) [1]. Compound 7d, EGFR-IN-60, demonstrates cytotoxic action against cancer cells at 0.49–86.4% μM after 48 hours [1]. In HepG2, HCT-116, and MCF-7 cell lines, EGFR-IN-60 (compound 7d) (0-5.27 μM, 24 hours) causes an increase in G2/M phase cells and triggers apoptosis [1]. Compound 7d, or EGFR-IN-60, can cause apoptosis by up-regulating Bax and down-regulating Bcl-2 at concentrations of 0 µM, 10 µM, and 24 hours [1]. |
| Cell Assay |
Cell proliferation assay [1] Cell Types: hepatocytes (HepG2), colorectal (HCT-116), breast cancer (MCF-7) Cancer cell Tested Concentrations: 3.25-88.46 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibition of HepG2 cells, HCT -116 cells and MCF-7 cells, the IC50 values are 4.46 μM, 5.27 μM and 3.25 μM respectively. Cytotoxicity assay [1] Cell Types: overexpressing EGFRWT human epidermoid cancer cells (A431), mutant EGFRT790M cells NSCLC (H1975), lung fibroblasts (WI38), amniotic epithelial cells (WISH) Tested Concentrations: 0.49-86.4 μM Incubation Duration: 48 Experimental Results: It has cytotoxic activity against A431, H1975, WI38, and WISH, with IC50 values of 4.96 μM, 1.32 μM, 64.27 μM, and 46.38 μM respectively. Cell cycle analysis [1] Cell Types: HepG2, HCT-116, MCF-7 Tested Concentrations: 0 μM, 3.25 μM, 4.46 μM, 5.27 μM Incubation Duration: 24 hrs (hours) Experimental Results: Result in increased G2/M phase percentage in HepG2, HCT- 116. In the MCF-7 cell line, the cells ranged from 14.09% to 25.66%, 15.87% to 38.51%, and 10.95% to 41.60% respe |
| References |
[1]. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Bioorg Chem. 2020 Dec;105:104274. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |